Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Piperidines"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 290
Tytuł:
Effectiveness of oral tofacitinib treatment on patients with moderate-to-severe alopecia areata in Iran.
Autorzy:
Asilian A; Department of Dermatology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.; Department of Dermatology, Skin and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Mohammadian P; Department of Dermatology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.; Department of Dermatology, Skin and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Shahmoradi Z; Department of Dermatology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.; Department of Dermatology, Skin and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Pokaż więcej
Źródło:
Journal of cosmetic dermatology [J Cosmet Dermatol] 2024 Mar; Vol. 23 (3), pp. 886-890. Date of Electronic Publication: 2023 Nov 07.
Typ publikacji:
Journal Article
MeSH Terms:
Alopecia Areata*/drug therapy
Piperidines*
Pyrimidines*
Humans ; Iran ; Pyrroles/adverse effects ; Alopecia/drug therapy ; Alopecia/chemically induced
SCR Disease Name:
Diffuse alopecia
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Changes in HLA-B27 Transgenic Rat Fecal Microbiota Following Tofacitinib Treatment and Ileocecal Resection Surgery: Implications for Crohn's Disease Management.
Autorzy:
Blondeaux A; U1286-INFINITE-Institute for Translational Research in Inflammation, CHU Lille, Inserm, Univ. Lille, F-59000 Lille, France.; Department of Hepato-Gastroenterology, Lille University Hospital, 59037 Lille, France.
Valibouze C; U1286-INFINITE-Institute for Translational Research in Inflammation, CHU Lille, Inserm, Univ. Lille, F-59000 Lille, France.; Department of Hepato-Gastroenterology, Lille University Hospital, 59037 Lille, France.
Speca S; U1286-INFINITE-Institute for Translational Research in Inflammation, CHU Lille, Inserm, Univ. Lille, F-59000 Lille, France.
Rousseaux C; Intestinal Biotech Development, 1 Avenue Oscar Lambret, 59045 Lille, France.
Dubuquoy C; Intestinal Biotech Development, 1 Avenue Oscar Lambret, 59045 Lille, France.
Blanquart H; GenoScreen, 1 Rue du Pr Calmette, 59000 Lille, France.
Zerbib P; U1286-INFINITE-Institute for Translational Research in Inflammation, CHU Lille, Inserm, Univ. Lille, F-59000 Lille, France.; Department of Hepato-Gastroenterology, Lille University Hospital, 59037 Lille, France.
Desreumaux P; U1286-INFINITE-Institute for Translational Research in Inflammation, CHU Lille, Inserm, Univ. Lille, F-59000 Lille, France.; Department of Hepato-Gastroenterology, Lille University Hospital, 59037 Lille, France.
Foligné B; U1286-INFINITE-Institute for Translational Research in Inflammation, CHU Lille, Inserm, Univ. Lille, F-59000 Lille, France.
Titécat M; U1286-INFINITE-Institute for Translational Research in Inflammation, CHU Lille, Inserm, Univ. Lille, F-59000 Lille, France.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Feb 10; Vol. 25 (4). Date of Electronic Publication: 2024 Feb 10.
Typ publikacji:
Journal Article
MeSH Terms:
Crohn Disease*/drug therapy
Crohn Disease*/surgery
Crohn Disease*/complications
Inflammatory Bowel Diseases*/drug therapy
Inflammatory Bowel Diseases*/complications
Microbiota*
Piperidines*
Pyrimidines*
Rats ; Animals ; Rats, Transgenic ; HLA-B27 Antigen ; Disease Management
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Comparison of Tepotinib, Paclitaxel, or Ramucirumab Efficacy According to the Copy Number or Phosphorylation Status of the MET Gene: Doublet Treatment versus Single Agent Treatment.
Autorzy:
Sohn SH; Hallym Translational Research Institute, Hallym University Sacred Heart Hospital, Anyang-si 14066, Republic of Korea.
Sul HJ; Hallym Translational Research Institute, Hallym University Sacred Heart Hospital, Anyang-si 14066, Republic of Korea.
Kim BJ; Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Anyang-si 14068, Republic of Korea.
Zang DY; Hallym Translational Research Institute, Hallym University Sacred Heart Hospital, Anyang-si 14066, Republic of Korea.; Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Anyang-si 14068, Republic of Korea.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Feb 01; Vol. 25 (3). Date of Electronic Publication: 2024 Feb 01.
Typ publikacji:
Journal Article
MeSH Terms:
Piperidines*
Pyridazines*
Pyrimidines*
Ramucirumab*
Stomach Neoplasms*/drug therapy
Proto-Oncogene Proteins c-met*/genetics
Proto-Oncogene Proteins c-met*/metabolism
Humans ; Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized/pharmacology ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; DNA Copy Number Variations ; Paclitaxel ; Phosphorylation
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A study protocol for an open-label, single-arm, single-center phase I clinical study on tolerability, safety, and efficacy of dalpiciclib combined with apatinib in the treatment of patients with advanced or metastatic sarcoma.
Autorzy:
Huang H; Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing, China.
Zhang H; Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, China.
Cao B; Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing, China.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2024 Feb; Vol. 15 (5), pp. 427-433. Date of Electronic Publication: 2024 Jan 11.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Antineoplastic Agents*/therapeutic use
Sarcoma*/drug therapy
Sarcoma*/pathology
Piperidines*
Pyridines*
Pyrimidines*
Humans ; Phosphatidylinositol 3-Kinases ; Clinical Trials, Phase I as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
First-Line Alectinib vs. Brigatinib in Advanced Non-Small Cell Lung Cancer with ALK Rearrangement: Real-World Data.
Autorzy:
Jeon Y; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Park S; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Jung HA; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Sun JM; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Lee SH; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Ahn JS; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Ahn MJ; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Pokaż więcej
Źródło:
Cancer research and treatment [Cancer Res Treat] 2024 Jan; Vol. 56 (1), pp. 61-69. Date of Electronic Publication: 2023 Jul 14.
Typ publikacji:
Observational Study; Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Carbazoles*
Organophosphorus Compounds*
Pyrimidines*
Humans ; Piperidines/adverse effects ; Protein Kinase Inhibitors/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Population pharmacokinetic and pharmacodynamic modeling of evobrutinib in healthy adult participants.
Autorzy:
Papasouliotis O; Merck Institute for Pharmacometrics, Lausanne, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany.
Mitchell D; Certara, Broomfield, Colorado, USA.
Girard P; Merck Institute for Pharmacometrics, Lausanne, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany.
Dyroff M; EMD Serono, Billerica, Massachusetts, USA.
Pokaż więcej
Źródło:
Clinical and translational science [Clin Transl Sci] 2022 Dec; Vol. 15 (12), pp. 2899-2908. Date of Electronic Publication: 2022 Oct 17.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Pyrimidines*
Piperidines*
Humans ; Adult ; Healthy Volunteers ; Fasting
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Suppression of IL-12/IL-23 p40 subunit in the skin and blood of psoriasis patients by Tofacitinib is dependent on active interferon-γ signaling in dendritic cells: Implications for the treatment of psoriasis and interferon-driven diseases.
Autorzy:
Vincken NLA; Center for Translational Immunology, Department of Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.; Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Welsing PMJ; Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Silva-Cardoso SC; Center for Translational Immunology, Department of Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.; Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Bekker CPJ; Center for Translational Immunology, Department of Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.; Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Lopes AP; Center for Translational Immunology, Department of Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.; Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Olde Nordkamp M; Center for Translational Immunology, Department of Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.; Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Leijten EFA; Center for Translational Immunology, Department of Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.; Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Radstake TRDJ; Center for Translational Immunology, Department of Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.; Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Angiolilli C; Center for Translational Immunology, Department of Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.; Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Pokaż więcej
Źródło:
Experimental dermatology [Exp Dermatol] 2022 Jun; Vol. 31 (6), pp. 962-969. Date of Electronic Publication: 2022 Mar 21.
Typ publikacji:
Journal Article
MeSH Terms:
Interferon-gamma*/metabolism
Interleukin-12 Subunit p40*/antagonists & inhibitors
Interleukin-12 Subunit p40*/blood
Interleukin-12 Subunit p40*/metabolism
Janus Kinase Inhibitors*/pharmacology
Janus Kinase Inhibitors*/therapeutic use
Piperidines*/pharmacology
Piperidines*/therapeutic use
Psoriasis*/drug therapy
Pyrimidines*/pharmacology
Pyrimidines*/therapeutic use
Skin*/drug effects
Skin*/immunology
Arthritis, Psoriatic/drug therapy ; Dendritic Cells/immunology ; Humans ; Lipopolysaccharides/immunology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis.
Autorzy:
Verstockt B; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.; Translational Research in Gastrointestinal Disorders, Department of Chronic Disease, Metabolism and Ageing, KU Leuven, Leuven, Belgium.
Volk V; Institute for Pathology, Hannover Medical School, Hannover, Germany.
Jaeckel C; Institute of Clinical Molecular Biology, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany.
Alsoud D; Translational Research in Gastrointestinal Disorders, Department of Chronic Disease, Metabolism and Ageing, KU Leuven, Leuven, Belgium.
Sabino J; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.; Translational Research in Gastrointestinal Disorders, Department of Chronic Disease, Metabolism and Ageing, KU Leuven, Leuven, Belgium.
Nikolaus S; Department of Internal Medicine I, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany.
Outtier A; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
Krönke N; Institute for Pathology, Hannover Medical School, Hannover, Germany.
Feuerhake F; Institute for Pathology, Hannover Medical School, Hannover, Germany.
De Hertogh G; Laboratory of Morphology and Molecular Pathology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
Rosenstiel P; Institute of Clinical Molecular Biology, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany.; Department of Internal Medicine I, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany.
Vermeire S; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.; Translational Research in Gastrointestinal Disorders, Department of Chronic Disease, Metabolism and Ageing, KU Leuven, Leuven, Belgium.
Schreiber S; Institute of Clinical Molecular Biology, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany.; Department of Internal Medicine I, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany.
Ferrante M; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.; Translational Research in Gastrointestinal Disorders, Department of Chronic Disease, Metabolism and Ageing, KU Leuven, Leuven, Belgium.
Aden K; Institute of Clinical Molecular Biology, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany.; Department of Internal Medicine I, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2022 Jul; Vol. 56 (2), pp. 282-291. Date of Electronic Publication: 2022 Apr 28.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Colitis, Ulcerative*/diagnosis
Colitis, Ulcerative*/drug therapy
Janus Kinase Inhibitors*/therapeutic use
Piperidines*/therapeutic use
Pyrimidines*/therapeutic use
STAT3 Transcription Factor*/metabolism
Humans ; Phosphorylation ; Remission Induction ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Tofacitinib improved peripheral endothelial dysfunction and brain-derived neurotrophic factor levels in the rat adjuvant-induced arthritis model.
Autorzy:
Totoson P; PEPITE EA4267, FHU INCREASE, Université Bourgogne Franche-Comté, Besançon, France.
Peyronnel C; PEPITE EA4267, FHU INCREASE, Université Bourgogne Franche-Comté, Besançon, France.
Quirié A; INSERM UMR1093-CAPS, Université Bourgogne Franche-Comté, UFR Sciences de Santé, Dijon, France.
Pédard M; INSERM UMR1093-CAPS, Université Bourgogne Franche-Comté, UFR Sciences de Santé, Dijon, France.
Cefis M; INSERM UMR1093-CAPS, Université Bourgogne Franche-Comté, UFR Sciences de Santé, Dijon, France.
Bermont L; Service de Biochimie médicale, CHRU Besançon, Besançon, France.
Prigent-Tessier A; INSERM UMR1093-CAPS, Université Bourgogne Franche-Comté, UFR Sciences de Santé, Dijon, France.
Prati C; PEPITE EA4267, FHU INCREASE, Université Bourgogne Franche-Comté, Besançon, France.; Service de Rhumatologie, CHRU Besançon, Besançon, France.
Tournier M; PEPITE EA4267, FHU INCREASE, Université Bourgogne Franche-Comté, Besançon, France.
Wendling D; Service de Rhumatologie, CHRU Besançon, Besançon, France.; EA 4266 'Agents Pathogènes et Inflammation', EPILAB, Université Bourgogne Franche-Comté, Besançon, France.
Marie C; INSERM UMR1093-CAPS, Université Bourgogne Franche-Comté, UFR Sciences de Santé, Dijon, France.
Demougeot C; PEPITE EA4267, FHU INCREASE, Université Bourgogne Franche-Comté, Besançon, France.
Pokaż więcej
Źródło:
Fundamental & clinical pharmacology [Fundam Clin Pharmacol] 2022 Apr; Vol. 36 (2), pp. 363-374. Date of Electronic Publication: 2021 Oct 26.
Typ publikacji:
Journal Article
MeSH Terms:
Arthritis, Experimental*/chemically induced
Arthritis, Experimental*/drug therapy
Brain-Derived Neurotrophic Factor*/metabolism
Piperidines*/pharmacology
Piperidines*/therapeutic use
Pyrimidines*/pharmacology
Pyrimidines*/therapeutic use
Animals ; Biological Factors ; Endothelium, Vascular ; Rats
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Protective Effect of CP690550 in MPTP-Induced Parkinson's Like Behavioural, Biochemical and Histological Alterations in Mice.
Autorzy:
Alshammari A; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Post Box 2455, Riyadh, 11451, Saudi Arabia.
Alharbi M; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Post Box 2455, Riyadh, 11451, Saudi Arabia.
Albekairi NA; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Post Box 2455, Riyadh, 11451, Saudi Arabia.
Albekairi TH; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Post Box 2455, Riyadh, 11451, Saudi Arabia.
Alharbi OO; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Post Box 2455, Riyadh, 11451, Saudi Arabia.
Yeapuri P; Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Singh S; Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Export Promotion Industrial Park (EPIP) Zandaha Road, Dist: Vaishali, 844102, Bihar, India. .
Pokaż więcej
Źródło:
Neurotoxicity research [Neurotox Res] 2022 Apr; Vol. 40 (2), pp. 564-572. Date of Electronic Publication: 2022 Apr 02.
Typ publikacji:
Journal Article
MeSH Terms:
Neuroprotective Agents*/pharmacology
Parkinson Disease*/drug therapy
Parkinson Disease*/pathology
Piperidines*/pharmacology
Pyrimidines*/pharmacology
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine ; Animals ; Cytokines ; Disease Models, Animal ; Dopaminergic Neurons ; Mice ; Mice, Inbred C57BL ; Parkinson Disease, Secondary
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor.
Autorzy:
Zhang H; BeiGene USA, Inc., San Mateo, CA, USA.
Ou YC; BeiGene USA, Inc., San Mateo, CA, USA.
Su D; BeiGene (Beijing) Co., Ltd, Beijing, China.
Wang F; BeiGene (Beijing) Co., Ltd, Beijing, China.
Wang L; BeiGene (Beijing) Co., Ltd, Beijing, China.
Sahasranaman S; BeiGene USA, Inc., San Mateo, CA, USA.
Tang Z; BeiGene USA, Inc., San Mateo, CA, USA.
Pokaż więcej
Źródło:
Pharmacology research & perspectives [Pharmacol Res Perspect] 2021 Dec; Vol. 9 (6), pp. e00870.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Cytochrome P-450 Enzyme System/*drug effects
Membrane Transport Proteins/*drug effects
Piperidines/*administration & dosage
Protein Kinase Inhibitors/*administration & dosage
Pyrazoles/*administration & dosage
Pyrimidines/*administration & dosage
Agammaglobulinaemia Tyrosine Kinase/antagonists & inhibitors ; Animals ; Cytochrome P-450 Enzyme System/metabolism ; Dogs ; Drug Interactions ; Hepatocytes/drug effects ; Hepatocytes/metabolism ; Humans ; Inhibitory Concentration 50 ; Membrane Transport Proteins/metabolism ; Mice ; Microsomes, Liver/drug effects ; Microsomes, Liver/metabolism ; Piperidines/pharmacokinetics ; Piperidines/pharmacology ; Protein Kinase Inhibitors/pharmacokinetics ; Protein Kinase Inhibitors/pharmacology ; Pyrazoles/pharmacokinetics ; Pyrazoles/pharmacology ; Pyrimidines/pharmacokinetics ; Pyrimidines/pharmacology ; Rats
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study.
Autorzy:
Ebina K; Department of Musculoskeletal Regenerative Medicine, Osaka University Graduate School of Medicine, Osaka, Japan. .
Hirano T; Department of Rheumatology, Nishinomiya Municipal Hospital, Hyogo, Japan.
Maeda Y; Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan.; Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Osaka, Japan.
Yamamoto W; Department of Health Information Management, Kurashiki Sweet Hospital, Okayama, Japan.; Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Hashimoto M; Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan.; Department of Clinical Immunology, Osaka City University Graduate School of Medicine, Osaka, Japan.
Murata K; Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Onishi A; Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Jinno S; Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Hyogo, Japan.
Hara R; Department of Orthopaedic Surgery, Nara Medical University, Nara, Japan.
Son Y; First Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
Amuro H; First Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
Takeuchi T; Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Osaka, Japan.
Yoshikawa A; Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Osaka, Japan.
Katayama M; Department of Rheumatology, Osaka Red Cross Hospital, Osaka, Japan.
Yamamoto K; Information Technology Center, Wakayama Medical University, Wakayama, Japan.
Okita Y; Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan.
Hirao M; Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.
Etani Y; Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.
Kumanogoh A; Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan.; Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Osaka, Japan.
Okada S; Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.
Nakata K; Department of Health and Sport Sciences, Osaka University Graduate School of Medicine, Osaka, Japan.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2022 Jan 07; Vol. 12 (1), pp. 134. Date of Electronic Publication: 2022 Jan 07.
Typ publikacji:
Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Antirheumatic Agents/*therapeutic use
Arthritis, Rheumatoid/*drug therapy
Azetidines/*therapeutic use
Janus Kinase Inhibitors/*therapeutic use
Piperidines/*therapeutic use
Purines/*therapeutic use
Pyrazoles/*therapeutic use
Pyrimidines/*therapeutic use
Sulfonamides/*therapeutic use
Age Factors ; Aged ; Antirheumatic Agents/adverse effects ; Arthritis, Rheumatoid/diagnosis ; Arthritis, Rheumatoid/enzymology ; Azetidines/adverse effects ; Drug-Related Side Effects and Adverse Reactions/etiology ; Female ; Humans ; Janus Kinase Inhibitors/adverse effects ; Japan ; Male ; Middle Aged ; Piperidines/adverse effects ; Purines/adverse effects ; Pyrazoles/adverse effects ; Pyrimidines/adverse effects ; Registries ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Sex Factors ; Sulfonamides/adverse effects ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Dickkopf-1 Inhibition Reactivates Wnt/β-Catenin Signaling in Rhabdomyosarcoma, Induces Myogenic Markers In Vitro and Impairs Tumor Cell Survival In Vivo.
Autorzy:
Giralt I; Laboratory of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Gallo-Oller G; Laboratory of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Navarro N; Laboratory of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Zarzosa P; Laboratory of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Pons G; Laboratory of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Magdaleno A; Laboratory of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Segura MF; Laboratory of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Sábado C; Pediatric Oncology and Hematology Department, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Hladun R; Pediatric Oncology and Hematology Department, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Arango D; Group of Molecular Oncology, IRB Lleida, 25198 Lleida, Spain.
Sánchez de Toledo J; Laboratory of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Moreno L; Laboratory of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.; Pediatric Oncology and Hematology Department, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Gallego S; Laboratory of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.; Pediatric Oncology and Hematology Department, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Roma J; Laboratory of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2021 Nov 29; Vol. 22 (23). Date of Electronic Publication: 2021 Nov 29.
Typ publikacji:
Journal Article
MeSH Terms:
Intercellular Signaling Peptides and Proteins/*metabolism
Naphthalenes/*therapeutic use
Piperidines/*therapeutic use
Pyrimidines/*therapeutic use
Rhabdomyosarcoma/*drug therapy
Wnt Signaling Pathway/*drug effects
beta Catenin/*metabolism
Animals ; Case-Control Studies ; Cell Line, Tumor ; Focal Adhesion Protein-Tyrosine Kinases/metabolism ; Humans ; Mice, SCID ; Molecular Targeted Therapy ; Muscles/metabolism ; MyoD Protein/metabolism ; Myogenin/metabolism ; Naphthalenes/pharmacology ; Piperidines/pharmacology ; Pyrimidines/pharmacology ; RNA, Small Interfering/therapeutic use ; Rhabdomyosarcoma/etiology ; Rhabdomyosarcoma/metabolism ; Xenograft Model Antitumor Assays ; Mice
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Novel NFκB Inhibitor SC75741 Mitigates Chondrocyte Degradation and Prevents Activated Fibroblast Transformation by Modulating miR-21/GDF-5/SOX5 Signaling.
Autorzy:
Weng PW; Department of Orthopaedics, School of Medicine, College of Medicine, Taipei Medical University, Taipei City 110, Taiwan.; Department of Orthopaedics, Shuang Ho Hospital, Taipei Medical University, New Taipei City 23561, Taiwan.; Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei City 110, Taiwan.
Yadav VK; Department of Medical Research & Education, Taipei Medical University-Shuang Ho Hospital, New Taipei City 23561, Taiwan.
Pikatan NW; Department of Medical Research & Education, Taipei Medical University-Shuang Ho Hospital, New Taipei City 23561, Taiwan.
Fong IH; Department of Medical Research & Education, Taipei Medical University-Shuang Ho Hospital, New Taipei City 23561, Taiwan.
Lin IH; School of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei City 110, Taiwan.; Division of Periodontics, Department of Dentistry, Taipei Medical University-Shuang Ho Hospital, New Taipei City 23561, Taiwan.
Yeh CT; Department of Medical Research & Education, Taipei Medical University-Shuang Ho Hospital, New Taipei City 23561, Taiwan.; Department of Medical Laboratory Science and Biotechnology, Yuanpei University of Medical Technology, Hsinchu City 30015, Taiwan.
Lee WH; Department of Medical Research & Education, Taipei Medical University-Shuang Ho Hospital, New Taipei City 23561, Taiwan.; Department of Pathology, Taipei Medical University-Shuang Ho Hospital, New Taipei City 23561, Taiwan.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2021 Oct 14; Vol. 22 (20). Date of Electronic Publication: 2021 Oct 14.
Typ publikacji:
Journal Article
MeSH Terms:
Benzimidazoles/*pharmacology
Chondrocytes/*drug effects
Fibroblasts/*drug effects
NF-kappa B/*antagonists & inhibitors
Osteoarthritis/*drug therapy
Osteoarthritis/*metabolism
Piperidines/*pharmacology
Pyrimidines/*pharmacology
Thiazoles/*pharmacology
Animals ; Benzimidazoles/chemistry ; Cell Differentiation/genetics ; Chondrocytes/metabolism ; Chondrocytes/pathology ; Collagen Type IV/genetics ; Collagen Type IV/metabolism ; Disease Models, Animal ; Female ; Fibroblasts/metabolism ; Fibroblasts/pathology ; Gene Expression Regulation ; Growth Differentiation Factor 5/genetics ; Growth Differentiation Factor 5/metabolism ; Humans ; Interleukin-1beta/pharmacology ; MicroRNAs/metabolism ; NF-kappa B/metabolism ; Osteoarthritis/pathology ; Piperidines/chemistry ; Pyrimidines/chemistry ; Rats, Wistar ; SOXD Transcription Factors/genetics ; SOXD Transcription Factors/metabolism ; Signal Transduction/drug effects ; Synovial Membrane/pathology ; Thiazoles/chemistry ; Rats
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19.
Autorzy:
Kaliamurthi S; Centre for Research in Molecular Modeling & Department of Chemistry and Biochemistry, Concordia University, Montreal, QC H3G 1M8, Canada.
Selvaraj G; Centre for Research in Molecular Modeling & Department of Chemistry and Biochemistry, Concordia University, Montreal, QC H3G 1M8, Canada.
Selvaraj C; Computer Aided Drug Design and Molecular Modeling Lab, Department of Bioinformatics, Alagappa University, Karaikudi 630003, India.
Singh SK; Computer Aided Drug Design and Molecular Modeling Lab, Department of Bioinformatics, Alagappa University, Karaikudi 630003, India.
Wei DQ; The State Key Laboratory of Microbial Metabolism, College of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China.
Peslherbe GH; Centre for Research in Molecular Modeling & Department of Chemistry and Biochemistry, Concordia University, Montreal, QC H3G 1M8, Canada.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2021 Jun 30; Vol. 22 (13). Date of Electronic Publication: 2021 Jun 30.
Typ publikacji:
Journal Article
MeSH Terms:
Drug Repositioning*
Molecular Dynamics Simulation*
Adenine/*analogs & derivatives
Piperidines/*chemistry
Protein Kinase Inhibitors/*chemistry
Pyrazoles/*chemistry
Pyrimidines/*chemistry
Adenine/chemistry ; Adenine/metabolism ; Adenine/therapeutic use ; Agammaglobulinaemia Tyrosine Kinase/antagonists & inhibitors ; Agammaglobulinaemia Tyrosine Kinase/metabolism ; Angiotensin-Converting Enzyme 2/antagonists & inhibitors ; Angiotensin-Converting Enzyme 2/metabolism ; Binding Sites ; COVID-19/pathology ; COVID-19/virology ; Humans ; Molecular Docking Simulation ; Piperidines/metabolism ; Piperidines/therapeutic use ; Protein Kinase Inhibitors/metabolism ; Protein Kinase Inhibitors/therapeutic use ; Pyrazoles/metabolism ; Pyrazoles/therapeutic use ; Pyrimidines/metabolism ; Pyrimidines/therapeutic use ; SARS-CoV-2/isolation & purification ; SARS-CoV-2/metabolism ; Serine Endopeptidases/chemistry ; Serine Endopeptidases/metabolism ; Thermodynamics ; Viral Nonstructural Proteins/antagonists & inhibitors ; Viral Nonstructural Proteins/metabolism ; COVID-19 Drug Treatment
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose.
Autorzy:
Xiong W; Merck Institute of Pharmacokinetics (an affiliate of Merck KGaA, Darmstadt, Germany), Lausanne, Switzerland.
Friese-Hamim M; Merck KGaA, Darmstadt, Germany.
Johne A; Merck KGaA, Darmstadt, Germany.
Stroh C; Merck KGaA, Darmstadt, Germany.
Klevesath M; Merck KGaA, Darmstadt, Germany.
Falchook GS; Sarah Cannon Research Institute at HealthONE, Denver, Colorado, USA.
Hong DS; MD Anderson Cancer Center, Houston, Texas, USA.
Girard P; Merck Institute of Pharmacokinetics (an affiliate of Merck KGaA, Darmstadt, Germany), Lausanne, Switzerland.
El Bawab S; Merck KGaA, Darmstadt, Germany.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2021 May; Vol. 10 (5), pp. 428-440. Date of Electronic Publication: 2021 May 01.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Drug Evaluation, Preclinical*
Models, Theoretical*
Piperidines/*pharmacology
Protein Kinase Inhibitors/*pharmacology
Pyridazines/*pharmacology
Pyrimidines/*pharmacology
Administration, Oral ; Animals ; Clinical Trials, Phase II as Topic ; Dose-Response Relationship, Drug ; Humans ; Mice ; Piperidines/administration & dosage ; Piperidines/pharmacokinetics ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/pharmacokinetics ; Pyridazines/administration & dosage ; Pyridazines/pharmacokinetics ; Pyrimidines/administration & dosage ; Pyrimidines/pharmacokinetics ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Pharmacokinetics and Bioequivalence of 2 Immediate-Release Tofacitinib Tablet Formulations in Chinese Healthy Volunteers Under Fasting and Fed Conditions.
Autorzy:
Li X; Department of Pharmacy, The Third Hospital of Changsha, Changsha, Hunan, China.
Liu L; Department of Pharmacy, The Third Hospital of Changsha, Changsha, Hunan, China.
Deng Y; Department of Pharmacy, The Third Hospital of Changsha, Changsha, Hunan, China.
Li Y; Department of Pharmacy, The Third Hospital of Changsha, Changsha, Hunan, China.
Zhang P; Department of Pharmacy, The Third Hospital of Changsha, Changsha, Hunan, China.
Wang Y; Department of Pharmacy, The Third Hospital of Changsha, Changsha, Hunan, China.
Xu B; Department of Pharmacy, The Third Hospital of Changsha, Changsha, Hunan, China.
Feng J; Jangsu Sinomune Pharmaceutical Company Limited, Jiangsu, China.
Huang L; Jangsu Sinomune Pharmaceutical Company Limited, Jiangsu, China.
Pokaż więcej
Źródło:
Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2021 May; Vol. 10 (5), pp. 535-541. Date of Electronic Publication: 2020 Aug 07.
Typ publikacji:
Comparative Study; Journal Article; Randomized Controlled Trial
MeSH Terms:
Food-Drug Interactions*
Drugs, Generic/*administration & dosage
Janus Kinase Inhibitors/*administration & dosage
Piperidines/*administration & dosage
Pyrimidines/*administration & dosage
Adolescent ; Adult ; Area Under Curve ; Asian People ; Cross-Over Studies ; Drugs, Generic/adverse effects ; Drugs, Generic/pharmacokinetics ; Fasting ; Female ; Half-Life ; Humans ; Janus Kinase Inhibitors/adverse effects ; Janus Kinase Inhibitors/pharmacokinetics ; Male ; Piperidines/adverse effects ; Piperidines/pharmacokinetics ; Pyrimidines/adverse effects ; Pyrimidines/pharmacokinetics ; Tablets ; Therapeutic Equivalency ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Pertinent role of maintenance dose of oral tofacitinib in a child with alopecia totalis with a 2.5-year follow-up on low dose.
Autorzy:
Sardana K; Department of Dermatology, Venereology and Leprosy, Atal Bihari Vajpayee Institute of Medical Sciences & Dr. Ram Manohar Lohia Hospital, New Delhi, India.
Mathachan SR; Department of Dermatology, Venereology and Leprosy, Atal Bihari Vajpayee Institute of Medical Sciences & Dr. Ram Manohar Lohia Hospital, New Delhi, India.
Gupta P; Department of Medicine, Atal Bihari Vajpayee Institute of Medical Sciences & Dr. Ram Manohar Lohia Hospital, New Delhi, India.
Pokaż więcej
Źródło:
Journal of cosmetic dermatology [J Cosmet Dermatol] 2022 Sep; Vol. 21 (9), pp. 4091-4094. Date of Electronic Publication: 2022 Jan 08.
Typ publikacji:
Letter
MeSH Terms:
Alopecia Areata*
Pyrimidines*
Child ; Follow-Up Studies ; Humans ; Piperidines
Opinia redakcyjna
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Tofacitinib-induced subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis.
Autorzy:
Apaydın H; Department of Rheumatology, Ankara City Hospital, Ankara, Turkey.
Erten Ş; Department of Rheumatology, Ankara Yıldırım Beyazıt University Medical Faculty, Ankara, Turkey.
Pokaż więcej
Źródło:
Modern rheumatology case reports [Mod Rheumatol Case Rep] 2021 Jul; Vol. 5 (2), pp. 254-258. Date of Electronic Publication: 2021 Feb 18.
Typ publikacji:
Case Reports
MeSH Terms:
Arthritis, Rheumatoid*/complications
Lupus Erythematosus, Cutaneous*/chemically induced
Lupus Erythematosus, Cutaneous*/diagnosis
Piperidines*/adverse effects
Pyrimidines*/adverse effects
Female ; Humans ; Middle Aged
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Two cases of rheumatoid arthritis complicated by organising pneumonia successfully treated with tofacitinib therapy.
Autorzy:
Kodera T; Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Tsutsumi T; Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Oka Y; Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Takeda T; Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Shirota Y; Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Kameoka J; Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Pokaż więcej
Źródło:
Modern rheumatology case reports [Mod Rheumatol Case Rep] 2021 Jul; Vol. 5 (2), pp. 218-225. Date of Electronic Publication: 2021 Mar 31.
Typ publikacji:
Case Reports
MeSH Terms:
Arthritis, Rheumatoid*/complications
Arthritis, Rheumatoid*/drug therapy
Piperidines*/therapeutic use
Pneumonia*/complications
Pneumonia*/drug therapy
Pyrimidines*/therapeutic use
Aged ; Aged, 80 and over ; Female ; Humans ; Protein Kinase Inhibitors/therapeutic use ; Treatment Outcome
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 290

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies